The town of Zuers in the Austrian Alps provided a snowy setting for the eighth International Winter Conference on Alzheimer’s Disease. Scientists hunkered down for news updates on current trials and experimental treatments at all stages of the pipeline. Gabrielle Strobel summarizes select highlights on what's happening with immunotherapies, research targeting receptors, and synucleins, an effort to inject a phage therapy into the spine, and a project to bridge the treacherous gap between preclinical and clinical outcome measures by assessing how humans navigate across a physical space.